CAR T-Cell Therapies in Relapsed/Refractory Acute Lymphocytic Leukemia

Experts break down how to sequence CAR T, blinatumomab, inotuzumab and transplant in relapsed ALL, balancing MRD goals, burden and toxicity.

Experts explain how MRD testing, B-cell aplasia and CAR T persistence help predict lasting ALL remission and guide transplant timing.

Expert panel shares real-world steps to start CD20xCD3 bispecifics for relapsed DLBCL, coordinating outpatient care and managing CRS/ICANS.

Experts explain how MRD negativity, B-cell aplasia, and CAR T persistence help predict durable remission across ALL therapies and products.

Learn how modern CAR T products differ in CRS/ICANS risk, and why earlier referral expands options for CNS and extramedullary relapse.